vs
Side-by-side financial comparison of Claritev Corp (CTEV) and Inspire Medical Systems, Inc. (INSP). Click either name above to swap in a different company.
Claritev Corp is the larger business by last-quarter revenue ($246.6M vs $204.6M, roughly 1.2× Inspire Medical Systems, Inc.). On growth, Claritev Corp posted the faster year-over-year revenue change (6.2% vs 1.6%). Over the past eight quarters, Claritev Corp's revenue compounded faster (2.5% CAGR vs 2.2%).
Inspire Medical Systems, Inc. is a medical technology firm that develops, manufactures and commercializes implantable neurostimulation solutions for obstructive sleep apnea. Its core product serves patients intolerant to CPAP therapy, with main markets across North America, Europe, and select Asia-Pacific regions, operating in sleep medicine and otolaryngology segments.
CTEV vs INSP — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $246.6M | $204.6M |
| Net Profit | $-80.6M | — |
| Gross Margin | — | 86.5% |
| Operating Margin | -3.1% | 13.0% |
| Net Margin | -32.7% | — |
| Revenue YoY | 6.2% | 1.6% |
| Net Profit YoY | 41.6% | — |
| EPS (diluted) | $-4.88 | $-0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $204.6M | ||
| Q4 25 | $246.6M | $269.1M | ||
| Q3 25 | $246.0M | $224.5M | ||
| Q2 25 | $241.6M | $217.1M | ||
| Q1 25 | $231.3M | $201.3M | ||
| Q4 24 | $232.1M | $239.7M | ||
| Q3 24 | $230.5M | $203.2M | ||
| Q2 24 | $233.5M | $195.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-80.6M | $136.1M | ||
| Q3 25 | $-69.8M | $9.9M | ||
| Q2 25 | $-62.6M | $-3.6M | ||
| Q1 25 | $-71.3M | $3.0M | ||
| Q4 24 | $-138.0M | $35.2M | ||
| Q3 24 | $-391.4M | $18.5M | ||
| Q2 24 | $-576.7M | $9.8M |
| Q1 26 | — | 86.5% | ||
| Q4 25 | — | 86.6% | ||
| Q3 25 | — | 85.8% | ||
| Q2 25 | — | 84.0% | ||
| Q1 25 | — | 84.7% | ||
| Q4 24 | — | 85.0% | ||
| Q3 24 | — | 84.1% | ||
| Q2 24 | — | 84.8% |
| Q1 26 | — | 13.0% | ||
| Q4 25 | -3.1% | 17.1% | ||
| Q3 25 | 4.1% | 4.3% | ||
| Q2 25 | 6.9% | -1.5% | ||
| Q1 25 | 4.2% | -0.7% | ||
| Q4 24 | -17.8% | 13.3% | ||
| Q3 24 | -146.7% | 7.0% | ||
| Q2 24 | -224.4% | 2.6% |
| Q1 26 | — | — | ||
| Q4 25 | -32.7% | 50.6% | ||
| Q3 25 | -28.4% | 4.4% | ||
| Q2 25 | -25.9% | -1.7% | ||
| Q1 25 | -30.8% | 1.5% | ||
| Q4 24 | -59.4% | 14.7% | ||
| Q3 24 | -169.8% | 9.1% | ||
| Q2 24 | -247.0% | 5.0% |
| Q1 26 | — | $-0.39 | ||
| Q4 25 | $-4.88 | $4.57 | ||
| Q3 25 | $-4.23 | $0.34 | ||
| Q2 25 | $-3.81 | $-0.12 | ||
| Q1 25 | $-4.38 | $0.10 | ||
| Q4 24 | $-8.49 | $1.17 | ||
| Q3 24 | $-24.25 | $0.60 | ||
| Q2 24 | $-35.78 | $0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.8M | $98.9M |
| Total DebtLower is stronger | $4.6B | — |
| Stockholders' EquityBook value | $-173.9M | $792.3M |
| Total Assets | $4.9B | $911.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $98.9M | ||
| Q4 25 | $16.8M | $308.3M | ||
| Q3 25 | $39.2M | $322.6M | ||
| Q2 25 | $56.4M | $300.9M | ||
| Q1 25 | $23.1M | $369.2M | ||
| Q4 24 | $16.8M | $445.5M | ||
| Q3 24 | $86.6M | $411.0M | ||
| Q2 24 | $48.8M | $439.7M |
| Q1 26 | — | — | ||
| Q4 25 | $4.6B | — | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $4.5B | — |
| Q1 26 | — | $792.3M | ||
| Q4 25 | $-173.9M | $781.2M | ||
| Q3 25 | $-101.8M | $666.5M | ||
| Q2 25 | $-39.9M | $677.8M | ||
| Q1 25 | $14.8M | $635.7M | ||
| Q4 24 | $84.0M | $689.7M | ||
| Q3 24 | $207.6M | $696.6M | ||
| Q2 24 | $603.4M | $638.1M |
| Q1 26 | — | $911.4M | ||
| Q4 25 | $4.9B | $907.3M | ||
| Q3 25 | $5.0B | $807.7M | ||
| Q2 25 | $5.1B | $802.2M | ||
| Q1 25 | $5.1B | $730.8M | ||
| Q4 24 | $5.2B | $808.4M | ||
| Q3 24 | $5.3B | $796.2M | ||
| Q2 24 | $5.7B | $728.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 304.87× | — | ||
| Q4 24 | 53.67× | — | ||
| Q3 24 | 21.73× | — | ||
| Q2 24 | 7.48× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $66.3M | — |
| Free Cash FlowOCF − Capex | $36.4M | — |
| FCF MarginFCF / Revenue | 14.8% | — |
| Capex IntensityCapex / Revenue | 12.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $66.3M | $52.5M | ||
| Q3 25 | $19.9M | $68.5M | ||
| Q2 25 | $61.2M | $2.7M | ||
| Q1 25 | $-30.1M | $-6.7M | ||
| Q4 24 | $-33.4M | $69.2M | ||
| Q3 24 | $72.8M | $52.3M | ||
| Q2 24 | $18.5M | $-78.0K |
| Q1 26 | — | — | ||
| Q4 25 | $36.4M | $41.8M | ||
| Q3 25 | $-16.3M | $58.1M | ||
| Q2 25 | $36.6M | $-6.3M | ||
| Q1 25 | $-68.9M | $-15.1M | ||
| Q4 24 | $-63.8M | $62.2M | ||
| Q3 24 | $41.1M | $44.3M | ||
| Q2 24 | $-7.0M | $-12.5M |
| Q1 26 | — | — | ||
| Q4 25 | 14.8% | 15.5% | ||
| Q3 25 | -6.6% | 25.9% | ||
| Q2 25 | 15.2% | -2.9% | ||
| Q1 25 | -29.8% | -7.5% | ||
| Q4 24 | -27.5% | 25.9% | ||
| Q3 24 | 17.8% | 21.8% | ||
| Q2 24 | -3.0% | -6.4% |
| Q1 26 | — | — | ||
| Q4 25 | 12.1% | 4.0% | ||
| Q3 25 | 14.7% | 4.6% | ||
| Q2 25 | 10.2% | 4.1% | ||
| Q1 25 | 16.8% | 4.2% | ||
| Q4 24 | 13.1% | 2.9% | ||
| Q3 24 | 13.8% | 3.9% | ||
| Q2 24 | 10.9% | 6.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.39× | ||
| Q3 25 | — | 6.90× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -2.24× | ||
| Q4 24 | — | 1.96× | ||
| Q3 24 | — | 2.83× | ||
| Q2 24 | — | -0.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
